Perrigo Company PLC (PRGO) - Net Assets

Latest as of March 2026: $2.50 Billion USD

Based on the latest financial reports, Perrigo Company PLC (PRGO) has net assets worth $2.50 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.98 Billion) and total liabilities ($5.48 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Perrigo Company PLC asset portfolio for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets $2.50 Billion
% of Total Assets 31.3%
Annual Growth Rate 8.49%
5-Year Change -43.02%
10-Year Change -50.73%
Growth Volatility 48.07

Perrigo Company PLC - Net Assets Trend (1991–2025)

This chart illustrates how Perrigo Company PLC's net assets have evolved over time, based on quarterly financial data. Check Perrigo Company PLC tangible equity quality to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Perrigo Company PLC (1991–2025)

The table below shows the annual net assets of Perrigo Company PLC from 1991 to 2025. For live valuation and market cap data, see market cap of Perrigo Company PLC.

Year Net Assets Change
2025-12-31 $2.94 Billion -32.04%
2024-12-31 $4.32 Billion -9.41%
2023-12-31 $4.77 Billion -1.53%
2022-12-31 $4.84 Billion -6.01%
2021-12-31 $5.15 Billion -8.90%
2020-12-31 $5.66 Billion -2.57%
2019-12-31 $5.80 Billion +2.40%
2018-12-31 $5.67 Billion -8.14%
2017-12-31 $6.17 Billion +3.58%
2016-12-31 $5.96 Billion -40.64%
2015-12-31 $10.04 Billion +15.44%
2014-12-31 $8.69 Billion +0.01%
2013-12-31 $8.69 Billion +272.67%
2012-12-31 $2.33 Billion +25.91%
2011-12-31 $1.85 Billion +21.01%
2010-12-31 $1.53 Billion +40.63%
2009-12-31 $1.09 Billion +18.09%
2008-12-31 $921.92 Million -1.26%
2007-12-31 $933.72 Million +23.76%
2006-12-31 $754.47 Million +17.75%
2005-12-31 $640.74 Million +8.45%
2004-12-31 $590.84 Million +10.18%
2003-12-31 $536.23 Million +19.58%
2002-12-31 $448.42 Million +7.76%
2001-12-31 $416.14 Million +7.84%
2000-12-31 $385.88 Million +6.08%
1999-12-31 $363.75 Million +2.52%
1998-12-31 $354.80 Million +2.69%
1997-12-31 $345.50 Million -18.53%
1996-12-31 $424.10 Million +11.25%
1995-12-31 $381.20 Million +11.92%
1994-12-31 $340.60 Million +5.38%
1993-12-31 $323.20 Million +37.53%
1992-12-31 $235.00 Million +27.93%
1991-12-31 $183.70 Million --

Equity Component Analysis

This analysis shows how different components contribute to Perrigo Company PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 367750000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $6.61 Billion 225.11%
Other Comprehensive Income $14.10 Million 0.48%
Total Equity $2.94 Billion 100.00%

Perrigo Company PLC Competitors by Market Cap

The table below lists competitors of Perrigo Company PLC ranked by their market capitalization.

Company Market Cap
Arcelik AS
IS:ARCLK
$1.45 Billion
Scientex Bhd
KLSE:4731
$1.45 Billion
Heineken Bhd
KLSE:3255
$1.45 Billion
E-Mart
KO:139480
$1.45 Billion
Blackbaud Inc
NASDAQ:BLKB
$1.45 Billion
BGF Retail Co Ltd
KO:282330
$1.45 Billion
CMST Development Co Ltd
SHG:600787
$1.45 Billion
Gunkul Engineering Public Company Limited
BK:GUNKUL
$1.45 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Perrigo Company PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 4,319,400,000 to 2,935,500,000, a change of -1,383,900,000 (-32.0%).
  • Net loss of 1,425,400,000 reduced equity.
  • Dividend payments of 159,300,000 reduced retained earnings.
  • Other comprehensive income increased equity by 176,500,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-1.43 Billion -48.56%
Dividends Paid $159.30 Million -5.43%
Other Comprehensive Income $176.50 Million +6.01%
Other Changes $24.30 Million +0.83%
Total Change $- -32.04%

Book Value vs Market Value Analysis

This analysis compares Perrigo Company PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.49x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 3.98x to 0.49x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1991-12-31 $2.63 $10.47 x
1992-12-31 $3.06 $10.47 x
1993-12-31 $4.19 $10.47 x
1994-12-31 $4.45 $10.47 x
1995-12-31 $4.90 $10.47 x
1996-12-31 $5.48 $10.47 x
1997-12-31 $4.61 $10.47 x
1998-12-31 $4.72 $10.47 x
1999-12-31 $4.93 $10.47 x
2000-12-31 $5.21 $10.47 x
2001-12-31 $5.58 $10.47 x
2002-12-31 $6.30 $10.47 x
2003-12-31 $7.42 $10.47 x
2004-12-31 $7.64 $10.47 x
2005-12-31 $6.81 $10.47 x
2006-12-31 $8.04 $10.47 x
2007-12-31 $9.81 $10.47 x
2008-12-31 $9.85 $10.47 x
2009-12-31 $11.71 $10.47 x
2010-12-31 $16.35 $10.47 x
2011-12-31 $19.67 $10.47 x
2012-12-31 $24.67 $10.47 x
2013-12-31 $75.20 $10.47 x
2014-12-31 $75.21 $10.47 x
2015-12-31 $71.79 $10.47 x
2016-12-31 $41.58 $10.47 x
2017-12-31 $43.27 $10.47 x
2018-12-31 $40.98 $10.47 x
2019-12-31 $42.52 $10.47 x
2020-12-31 $41.55 $10.47 x
2021-12-31 $38.56 $10.47 x
2022-12-31 $36.00 $10.47 x
2023-12-31 $35.24 $10.47 x
2024-12-31 $31.44 $10.47 x
2025-12-31 $21.19 $10.47 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Perrigo Company PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -48.56%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -33.51%
  • • Asset Turnover: 0.50x
  • • Equity Multiplier: 2.91x
  • Recent ROE (-48.56%) is below the historical average (2.37%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1991 15.57% 6.98% 1.29x 1.73x $10.23 Million
1992 18.98% 7.81% 1.38x 1.76x $21.10 Million
1993 16.96% 8.19% 1.32x 1.57x $22.48 Million
1994 13.04% 6.19% 1.29x 1.63x $10.34 Million
1995 10.44% 5.12% 1.42x 1.44x $1.68 Million
1996 10.61% 5.33% 1.32x 1.51x $2.60 Million
1997 -14.95% -5.72% 1.51x 1.73x $-86.11 Million
1998 0.42% 0.17% 1.51x 1.64x $-33.91 Million
1999 5.32% 2.61% 1.42x 1.44x $-16.98 Million
2000 7.17% 3.67% 1.31x 1.49x $-10.93 Million
2001 12.06% 6.07% 1.39x 1.43x $8.58 Million
2002 12.05% 6.54% 1.28x 1.44x $9.21 Million
2003 15.02% 8.97% 1.18x 1.42x $26.94 Million
2004 -59.74% -34.47% 0.60x 2.89x $-412.07 Million
2005 11.14% 5.22% 0.78x 2.73x $7.33 Million
2006 9.78% 5.10% 0.75x 2.55x $-1.65 Million
2007 14.54% 7.45% 0.71x 2.76x $42.40 Million
2008 15.62% 7.18% 0.79x 2.75x $51.86 Million
2009 20.48% 9.81% 0.73x 2.85x $113.87 Million
2010 22.18% 12.31% 0.86x 2.09x $186.29 Million
2011 21.70% 12.66% 0.79x 2.17x $216.51 Million
2012 18.95% 12.48% 0.66x 2.30x $208.76 Million
2013 2.36% 5.06% 0.29x 1.59x $-664.00 Million
2014 2.36% 5.06% 0.29x 1.60x $-664.07 Million
2015 1.27% 2.78% 0.24x 1.93x $-875.77 Million
2016 -67.35% -75.99% 0.38x 2.33x $-4.61 Billion
2017 1.94% 2.42% 0.43x 1.88x $-497.45 Million
2018 2.31% 2.77% 0.43x 1.94x $-435.80 Million
2019 2.52% 3.78% 0.34x 1.95x $-434.28 Million
2020 -2.88% -3.98% 0.36x 2.03x $-728.11 Million
2021 -1.34% -1.66% 0.40x 2.02x $-584.07 Million
2022 -2.90% -3.16% 0.40x 2.28x $-624.81 Million
2023 -0.27% -0.27% 0.43x 2.27x $-489.49 Million
2024 -3.98% -3.93% 0.45x 2.23x $-603.74 Million
2025 -48.56% -33.51% 0.50x 2.91x $-1.72 Billion

Industry Comparison

This section compares Perrigo Company PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $164,559,673
  • Average return on equity (ROE) among peers: -62.52%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Perrigo Company PLC (PRGO) $2.50 Billion 15.57% 2.19x $1.45 Billion
Aurora Cannabis Inc (ACB) $602.92 Million -11.50% 0.39x $158.46 Million
Akanda Corp (AKAN) $26.90 Million -43.34% 0.45x $4.25 Million
Akebia Ther (AKBA) $-2.68 Million 0.00% 0.00x $340.21 Million
Alkermes Plc (ALKS) $58.35 Million -183.19% 3.99x $7.49 Billion
Amylyx Pharmaceuticals Inc (AMLX) $305.26 Million -47.41% 0.09x $1.64 Billion
Amphastar P (AMPH) $448.72 Million 0.31% 0.41x $854.96 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $-175.94 Million 0.00% 0.00x $5.21 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $208.93 Million -62.22% 17.18x $3.57 Billion
Anika Therapeutics Inc (ANIK) $153.99 Million -36.62% 0.32x $196.52 Million
ANI Pharmaceuticals Inc (ANIP) $19.15 Million -241.27% 1.34x $1.77 Billion

About Perrigo Company PLC

NYSE:PRGO USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.45 Billion
Market Cap Rank
#7270 Global
#2215 in USA
Share Price
$10.47
Change (1 day)
-1.13%
52-Week Range
$9.25 - $28.43
All Time High
$137.98
About

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and ora… Read more